Article

Baker, S. G. & Kaprio, J. Common susceptibility genes for cancer: search for the end of the rainbow. BMJ 332, 1150-1152

University of Helsinki, Helsinki, Uusimaa, Finland
BMJ (online) (Impact Factor: 16.38). 06/2006; 332(7550):1150-2. DOI: 10.1136/bmj.332.7550.1150
Source: PubMed
0 Followers
 · 
77 Views
 · 
2 Downloads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The tobacco industry first began to promote the idea that a minority of smokers are 'genetically predisposed' to lung cancer in the 1950s. We used tobacco industry documents available as a result of litigation to investigate the role of the tobacco industry in funding the 'scientific bandwagon' described by Fujimura, in which genetics has come to dominate the cancer research agenda. From 1990-1995 inclusive, 52% of the project funding allocated by British Am erican Tobacco's Scientific Research Group went to genetic research, mainly based in universities and at one cancer charity. The largest project in volved a pharmacogenetic research unit, based in a UK medical school, which was established with the help of tobacco industry PR consultants in 1988. The unit received half its project funding from the industry in 1992. Its main aim was to identify a minority of smokers who are supposedly 'genetically susceptible' to lung cancer, so that smoking cessation measures could be targeted at them. This aim was adopted and promoted by influential scientists at the US National Institutes of Health and the UK Medical Research Council in the late 1980s, in the run up to the Human Genome Project. BAT's research funds were also used to counter claim s by others to have identified a unique 'genetic fingerprint' for tobacco smoke in lung cancer cells. We conclude that the tobacco industry has played a significant role in shaping research agendas, in particular, by prom oting the idea that individual genome screening would be of benefit to public health.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The Human Genome Project and the ensuing International HapMap Project were largely motivated by human health issues. But the distance from a DNA sequence variation to a novel disease gene is considerable; for complex diseases, closing this gap hinges on the premise that they arise mainly from heritable causes. Using cancer as an example of complex disease, we examine the scientific evidence for the hypothesis that human diseases result from interactions between genetic variants and the environment.
    Nature Reviews Genetics 01/2007; 7(12):958-65. DOI:10.1038/nrg2009 · 39.79 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To review the evidence implicating the deregulation of cyclin D1 in the pathogenesis of non-small cell lung cancer (NSCLC), and to discuss the opportunities for targeted clinical intervention. Data published until June 2006 are summarized, and previously unpublished results from our own research are included. In normal cells, cyclin D1 complexes with and activates cyclin-dependent kinases (CDK) and acts as a transcriptional regulator. The protein is frequently overexpressed in a wide range of cancers, sometimes coincident with CCND1 (cyclin D1) gene amplification (5-20% of tumours). A low level of somatic mutations have been seen in certain tumours. CCND1 is amplified in NSCLC and cyclin D1 is frequently overexpressed in tumours and pre-invasive bronchial lesions, generally from one parental allele. Mutation analyses revealed a frequent CCND1 gene polymorphism (A870G) that modulates alternative splicing and allows expression of an alternative cyclin D1 transcript (transcript cyclin D1b). The encoded cyclin D1b protein lacks a specific phosphorylation site required for nuclear export. Genotype has been correlated with the risk and/or severity of disease or drug response across a range of malignancies, including lung cancer. Together, these findings suggest a strong pathological role for cyclin D1 deregulation in bronchial neoplasia. Current data indicate that cyclin D1 overexpression is not a consequence of, but rather a pivotal element in the process of malignant transformation in the lung and other tissues. This understanding may open new avenues for lung cancer diagnosis, treatment and prevention.
    Lung Cancer 02/2007; 55(1):1-14. DOI:10.1016/j.lungcan.2006.09.024 · 3.74 Impact Factor
Show more

Preview

Download
2 Downloads
Available from